. Author manuscript; available in PMC: 2016 May 10.

Published in final edited form as: Bone Marrow Transplant. 2015 Dec 7;51(3):333–343. doi: 10.1038/bmt.2015.301

Table 4.

Mechanistic pre-clinical studies addressing the influence of pDC on GvHD and GvL

	Contributory or neutral role	Protective role
aGvHD	XRT-activated recipient-type pDC prime alloreactive donor T cells and cause aGvHD⁷⁷ ProGP-1-expanded host pDCs augment GvHD¹⁰³ Depletion of host cDCs and pDC does not attenuate GvHD⁷⁸ Increased pDC in G+P mobilized donor splenocyte grafts increased aGvHD clinical scores and intestine pathology scores in allogeneic recipient mice¹²⁸	p-preDC induce Tregs and reduce aGvHD^65,69 BM pDC attenuate aGvHD⁹⁰ p-preDC attenuate aGvHD^90–92 CCR9⁺ immature pDCs attenuate GI aGvHD⁸³ Pre-transplant FL given to BMT recipients reduces aGvHD via CD8α⁺ DC expansion⁵⁰ pDC (lin⁻HLA-DR⁺ CD11c⁻ CD123⁺) induce Tregs¹⁰⁶ Type I IFN protects against CD4-dependent aGvHD¹⁰⁹
GvL	p-preDCs promote Th1/type 1 CTL differentiation, enhancing GvL activity without increasing GvHD^91,92,107	Recipients of STAT1KO BM had increased pDCs, decreased GvHD, preserved GvL activity and enhanced OS compared with transplant recipients receiving WT BM¹¹¹

Abbreviations: aGvHD = acute GvHD; Allo = allogeneic; BM = bone marrow; CTL = cytotoxic T lymphocyte; FL = flt3 ligand; G = G-CSF; GM = GM-CSF; M = million; p-preDC = plasmacytoid precursor DC; P = plerixafor; PB = peripheral blood; ProGP-1 = progenipoietin (FL+G); XRT = radiation.